세계 오피오이드 시장 규모는 2024년 225억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 288억 달러에 달할 것이며, 2025-2033년 연평균 성장률(CAGR)은 2.65%를 보일 것으로 예측했습니다. 만성 통증 질환의 유병률 증가, 노인 인구 증가, 암 진단 증가, 의료 서비스 접근성 향상, 지속적인 연구개발(R&D) 노력, 소비자 인식 증가, 유리한 정부 규제 등이 시장을 이끄는 주요 요인으로 꼽힙니다.
만성 통증 증가
세계적으로 만성통증이 증가하고 있는 것이 오피오이드 산업 성장의 주요 원인입니다. 2021년 미국 성인의 20.9% 이상(5,160만 명)이 만성통증을 앓고 있으며, 6.9%(1,710만 명)가 심각한 만성통증(즉, 일상생활에 심각한 제한을 초래하는 통증)을 호소하고 있습니다. 수백만 명의 사람들이 관절염, 요통, 신경통, 요통 등의 질병으로 인한 만성 통증으로 고통받고 있으며, 효과적인 통증 관리 치료의 필요성을 절감하고 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 2019년부터 2021년까지 미국에서 약 5,320만 명(21.2%)이 의사로부터 관절염 진단을 받았다고 합니다. 그 결과, 오피오이드는 극심한 통증 치료에 효과적이기 때문에 의료진에 의해 처방되고 있습니다.
늘어나는 노인 인구
오피오이드 산업은 노인 인구 증가에 의해 주도되고 있습니다. 2022년 65세 이상 인구는 7억 7,100만 명으로 세계 인구의 약 10%를 차지합니다. 2022년에는 인도에서 14억 9,000만 명이 60세 이상으로 기록되어 전체 인구의 약 10.5%를 차지할 것으로 예측됩니다. 또한, 유럽연합(EU) 인구는 2023년 4억 4,880만 명에 달할 것으로 예상되며, 그 중 5분의 1 이상(21.3%)이 65세 이상이 될 것으로 예측됩니다. 노인은 퇴행성 관절 질환이나 암과 같은 노화 관련 질환으로 인해 만성 통증을 겪을 가능성이 높습니다. 이에 따라 통증 치료 옵션에 대한 니즈가 증가하고 있습니다. 미국에서는 65세 이상 성인 중 47%가 관절염 진단을 받은 것으로 추정됩니다. 또한, 골관절염은 두 번째로 흔한 류마티스 질환이며, 인도에서 22%에서 39%의 유병률을 보이는 가장 흔한 관절 질환입니다. 거의 65세 이상 여성의 45%가 증상이 있고, 65세 이상 여성의 70%에서 방사선학적 증거가 발견됩니다.
세계적으로 증가하는 암 발병률
특히 신흥국의 암 진단율 증가가 오피오이드 수요를 촉진하고 있습니다. 국제암연구소(IARC)는 2022년에는 2,000만 명의 암 환자가 새로 발생하고 970만 명이 사망할 것으로 추정하고 있습니다. 또한, 암 진단 후 5년 후 생존자 수는 5,350만 명으로 예상되고 있습니다. 또한, 평생 약 5명 중 1명이 암에 걸리며, 남성 9명 중 1명, 여성 12명 중 1명이 암으로 사망하고 있습니다. 암 환자는 종종 큰 통증을 경험하고, 오피오이드는 암 통증 치료의 중요한 요소입니다. 전 세계적으로 암 발병률이 증가함에 따라 효과적인 통증 관리에 대한 수요도 증가하여 오피오이드 산업의 성장을 견인하고 있습니다.
The global opioids market size reached USD 22.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 28.8 Billion by 2033, exhibiting a growth rate (CAGR) of 2.65% during 2025-2033. The rising incidence of chronic pain conditions, increasing elderly population, increase in cancer diagnoses, improved access to healthcare services, ongoing research and development (R&D) efforts, escalating consumer awareness, and favorable government regulations are some of the major factors propelling the market.
Increasing prevalence of chronic pain
The increasing incidence of chronic pain throughout the world is a primary driver of opioid industry growth. In 2021, over 20.9% of U.S. adults (51.6 million) suffered chronic pain, while 6.9% (17.1 million) reported high-impact chronic pain (i.e., pain that significantly limits daily activities). Millions of people suffer from chronic pain, which is commonly caused by ailments, such as arthritis, back difficulties, or neuropathic disorders, boosting the use of effective pain management treatments. In 2019-2021, around 53.2 million US individuals (21.2%) had arthritis diagnosed by a doctor, according to the Center for Disease Control and Prevention (CDC). As a result, opioids are prescribed by healthcare practitioners because of their effectiveness in treating severe pain.
Growing geriatric population
The opioids industry is driven by the growing geriatric population. In 2022, there were 771 million persons aged 65 and over, accounting for about 10% of the global population. In 2022, 14.9 crore people in India were recorded to be 60 years or older, accounting for approximately 10.5% of the total population. In addition, the population of the European Union (EU) was predicted to be 448.8 million in 2023, with more than one-fifth (21.3%) of it aged 65 and more. Geriatric individuals are more likely to endure chronic pain due to age-related disorders, such as degenerative joint disease and cancer. This has raised the need for pain treatment choices. It is estimated that among adults aged 65 and older, 47% are diagnosed with arthritis in the USA. Also, osteoarthritis is the second most common rheumatologic problem, and it is the most frequent joint disease with a prevalence of 22% to 39% in India. Nearly, 45% of women over the age of 65 years have symptoms while radiological evidence is found in 70% of those over 65 years.
Rising cancer rates across the globe
The increasing rate of cancer diagnoses, particularly in emerging nations, is fueling the demand for opioids. The International Agency for Research on Cancer (IARC) estimated that 20 million new cancer cases and 9.7 million deaths occurred in 2022. The expected number of persons who survived 5 years after a cancer diagnosis was 53.5 million. Furthermore, around one in every five persons develops cancer during their lifetime, with one in every nine men and one in every twelve women dying from the condition. Cancer patients frequently experience significant pain, and opioids are a key component of cancer pain therapy. As cancer rates increase internationally, so does the demand for effective pain management, driving the opioid industry expansion.
Oxycodone accounts for the majority of the market share
According to the opioids market statistics, oxycodone has emerged as a dominant product type owing to its potent pain-relieving properties, which make it highly effective in managing severe pain, including post-operative and cancer-related pain. Physicians often prescribe oxycodone when other pain management options prove insufficient. Moreover, the pharmaceutical industry has invested significantly in the development of extended-release formulations of oxycodone, offering prolonged pain relief with fewer dosing intervals. Additionally, oxycodone's versatility allows for various administration routes, including oral tablets, capsules, and intravenous formulations, catering to diverse patient needs, which, in turn, is propelling its adoption.
Pain management holds the largest share of the industry
Based on the opioid market trends, pain management accounted for the largest market share. Opioid's fundamental role in the healthcare sector and the increasing recognition of the importance of effectively addressing pain is fueling its adoption in pain management applications. Pain refers to a pervasive and complex medical issue affecting millions of individuals worldwide, and opioids are considered a crucial component in managing moderate to severe pain, especially in acute and chronic pain conditions, post-surgical recovery, and cancer-related pain. The sheer prevalence of pain-related conditions owing to the burgeoning geriatric population and the rising incidence of cancer diagnoses, thereby creating a sustained demand for effective pain relief methods, is bolstering the opioids market share.
According to the opioids market overview, hospital pharmacies represent a critical distribution channel as these settings are the first encounters of opioid prescriptions for patients, especially after surgeries or for acute pain management. They ensure controlled distribution and use, providing a direct link between the prescription and administration of opioids under medical supervision.
As per the opioids market analysis, retail pharmacies serve as the most accessible point for patients to fill opioid prescriptions for chronic pain management. They cater to the ongoing needs of patients outside the hospital setting, facilitating the continuity of care prescribed by healthcare providers. Retail pharmacies offer widespread availability, convenience, and, in some regions, counseling services to ensure safe use, boosting the opioid market revenue.
According to the opioids market report, drug stores offer a broader shopping experience with a particular focus on health. They provide a convenient option for patients to access their medications along with other healthcare products. The role of drug stores in the opioid industry underscores the balance between accessibility to necessary medications and the responsibility to limit access to prescription drugs to prevent abuse.
Online pharmacies represent a growing segment in the opioid market, offering patients convenience and lower prices for their medications. Moreover, rapid advancements in digital health technologies and changing consumer behaviors are favoring the shift toward online shopping. Along with this, online pharmacies increase access to pain management solutions in underserved or rural areas.
North America leads the market, accounting for the largest opioids market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for opioids.
As per the opioids market outlook, The North American region dominated the market share due to several factors, including a high prevalence of chronic pain conditions, such as back pain and osteoarthritis, an aging population, and the widespread use of opioids in pain management. In addition to this, improved healthcare infrastructure and increased awareness of pain management options have led to higher opioid prescription rates, positively impacting the opioid market demand. Moreover, specialized addiction treatment centers and pharmacies have emerged as distribution channels, addressing the demand for these medications. Furthermore, evolving regulations and prescribing practices, influenced by stricter guidelines and prescription monitoring programs, are influencing the opioid market growth.